Peng Li
No Rating Available
(Learn About Our Rating System)

Peng Li, MD, PhD

Languages spoken: English

  • Dr. Li is an assistant professor of pathology at the University of Utah School of Medicine. She received her MD and master of science in microbiology at Peking University Health Science Center in Beijing, China. Thereafter, she went on to complete a doctor of philosophy in molecular pharmacology and structural biology at Thomas Jefferson University in Philadelphia. She served as a pathology resident in anatomic and clinical pathology at the University of Utah School of Medicine in Salt Lake City, and subsequently relocated to California to pursue a hematopathology fellowship at Stanford University. She also completed a molecular genetic pathology fellowship at Baylor College of Medicine in Houston and she is board certified by the American Board of Pathology in anatomic and clinical pathology (AP/CP), as well as hematopathology and molecular genetic pathology. Dr. Li’s areas of interest include myeloid and lymphoid malignancies and her current research interests include genetic aspects of malignancy and myeloid neoplasms with germline predisposition.

    Board Certification

    American Board of Pathology (Clinical Path)
    American Board of Pathology (Sub: Anatomic Path)
    American Board of Pathology (Sub: Hematopathology)
    American Board of Pathology (Sub: Molecular Genetic Pathology)

  • Dr. Li is an assistant professor of pathology at the University of Utah School of Medicine. She received her MD and master of science in microbiology at Peking University Health Science Center in Beijing, China. Thereafter, she went on to complete a doctor of philosophy in molecular pharmacology and structural biology at Thomas Jefferson University in Philadelphia. She served as a pathology resident in anatomic and clinical pathology at the University of Utah School of Medicine in Salt Lake City, and subsequently relocated to California to pursue a hematopathology fellowship at Stanford University. She also completed a molecular genetic pathology fellowship at Baylor College of Medicine in Houston and she is board certified by the American Board of Pathology in anatomic and clinical pathology (AP/CP), as well as hematopathology and molecular genetic pathology. Dr. Li’s areas of interest include myeloid and lymphoid malignancies and her current research interests include genetic aspects of malignancy and myeloid neoplasms with germline predisposition.

    Board Certification and Academic Information

    Academic Departments Pathology -Primary
    Board Certification
    American Board of Pathology (Clinical Path)
    American Board of Pathology (Sub: Anatomic Path)
    American Board of Pathology (Sub: Hematopathology)
    American Board of Pathology (Sub: Molecular Genetic Pathology)

    Education history

    Fellowship Molecular Genetic Pathology - Baylor College of Medicine Fellow
    Hematopathology - Stanford University School of Medicine Fellow
    Residency Anatomic & Clinical Pathology - University of Utah School of Medicine/ARUP Laboratories Resident
    Clinical Pharmacology - National Institutes of Health/Thomas Jefferson University Hospital Fellow
    Research Fellow Pharmacology & Experimental Therapeutics - National Institutes of Health/Thomas Jefferson University Postdoctoral Research Fellow
    Molecular Pharmacology & Structural Biology - Thomas Jefferson University Ph.D.
    Graduate Training Microbiology - Peking University Health Science Center M.S.
    Medicine - Peking University Health Science Center M.D.

    Selected Publications

    Journal Article

    1. Tatarian J, Tupper Bs N, Li P, Feusier J, Abdo M, Hyter S, Gonzales PR, Zhang D, Woodroof J, Kelting S, Godwin AK, Cui W (2023). Morphologic, immunophenotypic, molecular genetic, and clinical characterization in patients with SRSF2-mutated acute myeloid leukemia. Am J Clin Pathol. (Read full article)
    2. Kavesh M, Mohebnasab M, Angel MR, Xie W, Raess PW, Cui W, Press RD, Yang G, Li P (2022). Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling. Blood Adv, 7(1), 40-45. (Read full article)
    3. Cantu MD, Kanagal-Shamanna R, Wang SA, Kadia T, Bueso-Ramos CE, Patel SS, Geyer JT, Tam W, Madanat Y, Li P, George TI, Nichols MM, Rogers HJ, Liu YC, Aggarwal N, Kurzer JH, Maracaja DLV, Hsi ED, Zaiem F, Babu D, Foucar K, Laczko D, Bagg A, Orazi A, Arber DA, Hasserjian RP, Weinberg OK (2023). Clinicopathologic and Molecular Analysis of Normal Karyotype Therapy-Related and De Novo Acute Myeloid Leukemia: A Multi-Institutional Study by the Bone Marrow Pathology Group. JCO Precis Oncol, 7, e2200400. (Read full article)
    4. Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z (2022). Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Mod Pathol, 35(10), 1411-1422. (Read full article)
    5. Wei Xie, Philipp W Raess, Jennifer Dunlap, Cristina Magallanes Hoyos, Hongmei Li, Peng Li, Ronan Swords, Susan B Olson, Fei Yang, Tauangtham Anekpuritanang, Shimin Hu, Joanna Wiszniewska, Guang Fan, Richard D Press, Stephen R Moore (2022). Adult acute myeloid leukemia patients with NUP98 rearrangement have frequent cryptic translocations and unfavorable outcome. Leuk Lymphoma, 1-10.
    6. Li P, White T, Xie W, Cui W, Peker D, Zeng G, Wang HY, Vagher J, Brown S, Williams M, Kovacsovics T, Patel JL (2021). AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia, 36(3), 664-674. (Read full article)
    7. Majd Jawad, Michelle Afkhami, Yi Ding, Xiaohui Zhang, Peng Li, Kim Young, Mina Xu, Wei Cui, Yiqing Zhao, Stephanie Halene, Rong He and Gang Zheng (2022). DNMT3A R882 mutations confer unique clinicopathologic features in MDS including a high risk of AML transformation. Front Oncol.
    8. Parcha V, Heindl B, Kalra R, Bress A, Rao S, Pandey A, Gower B, Irvin MR, McDonald MN, Li P, Arora G, Arora P (2022). Genetic European Ancestry and Incident Diabetes in Black Individuals: Insights From the SPRINT Trial. Circ Genom Precis Med, 15(1), e003468. (Read full article)
    9. Li P, Venkatachalam S, Ospina Cordona D, Wilson L, Kovacsovics T, Moser KA, Miles RR, Beck DB, George T, Tantravahi SK (2021). A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. Blood Adv, 6(2), 405-409. (Read full article)
    10. Zhang BM, Keegan A, Li P, Lindeman NI, Nagarajan R, Routbort MJ, Vasalos P, Kim AS, Merker JD (2020). An Overview of Characteristics of Clinical Next-Generation Sequencing-Based Testing for Hematologic Malignancies. Arch Pathol Lab Med, 145(9), 1110-1116. (Read full article)
    11. Jinping Lai, Katherine Y Garvey, Peng Li, Robert A Azevedo (2021). Primary Ovarian Melanoma Arising From a Mature Teratoma With Melanoma In Situ Present in the Ciliated Columnar and Squamous Epithelium in a Patient With Synchronous Skin Basal Cell Carcinoma. Int J Gynecol Pathol, 40(4), 383-390.
    12. Philippa Li, Dongwei Zhang, Jiehao Zhou, Peng Li, Yulei Shen, Zenggang Pan, Andrew G Evans, Xiaoyan Liao (2020). Hepatic involvement by T-cell neoplasms: a clinicopathologic study of 40 cases. Hum Pathol, 106, 1-12.

    Review

    1. Zheng G, Li P, Zhang X, Pan Z (2022). The fifth edition of the World Health Organization Classification and the International Consensus Classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications. [Review]. Curr Opin Hematol, 30(2), 53-63. (Read full article)

    Case Report

    1. Zhang D, Li P, Szankasi P, Liao X (2020). Mixed adenoneuroendocrine carcinoma of the gallbladder, amphicrine type: Case report and review of literature. Pathol Res Pract, 216(7), 152997. (Read full article)
    2. Tang Y, Li P, Cua D, Lai J (2019). Laryngeal Diffuse Large B-Cell Lymphoma Presenting as Laryngeal Stenosis. In Vivo, 34(1), 255-260. (Read full article)
    3. Bahr TM, Lozano-Chinga M, Agarwal AM, Meznarich JA, Yost CC, Li P, Reading NS, Prchal JT, Christensen RD (2020). A Novel Variant in G6PD (c.1375C>G) Identified from a Hispanic Neonate with Extreme Hyperbilirubinemia and Low G6PD Enzymatic Activity. Neonatology, 117(4), 532-535. (Read full article)

    Patent

    1. Li P (2019). Modulation of cyclic guanosine monophosphate levels to potentiate gastrointestinal tract protection from chemotherapy and radiation therapy. U.S. Patent No. 61/102, 203. Washington, D.C.:U.S. Patent and Trademark Office.
    2. Li P (2019). Modulation of cyclic guanosine monophosphate levels to potentiate gastrointestinal tract protection from chemotherapy and radiation therapy. U.S. Patent No. 61/102, 203. Washington, D.C.:U.S. Patent and Trademark Office.